Healthcare Providers and Services
Company Overview of Boston Heart Diagnostics Corporation
Boston Heart Diagnostics Corporation, a healthcare company, provides tests, information, and services and support for the management and prevention of heart diseases. It provides coronary heart disease (CHD) risk assessment tests; and disease management through lipid testing, tools, therapy guidelines, and patient support services for physicians, patients, and pharmaceutical. The company also offers personalized treatment options to patients with dyslipidemia to determine the efficacy of lipid adjusting drugs. In addition, Boston Heart Diagnostics Corporation provides the direct measurement of lipoprotein particle profiles, including high density lipoprotein (HDL) subpopulations, direct smal...
2 Central Street
Framingham, MA 01701-4163
Founded in 2007
Key Executives for Boston Heart Diagnostics Corporation
Vice President of Operations
Vice President and General Counsel
Compensation as of Fiscal Year 2013.
Boston Heart Diagnostics Corporation Key Developments
Boston Heart Diagnostics Corporation Launches FDA-Cleared MPO (Myeloperoxidase) Test
Mar 6 14
Boston Heart Diagnostics Corporation announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke. Boston Heart is a leader in the science of chronic disease risk assessment and patient management. The launch of MPO is an important addition to the suite of next-generation diagnostics the company already offers. More than lab results, Boston Heart gives healthcare providers the tools they need to identify risk, individualize treatment plans, and engage patients in preventing and reversing cardiovascular disease. Boston Heart offers the MPO test as an individual assay, or as part of a panel of other critical inflammation markers including hs-CRP and LpPLA. Unlike other MPO assays on the market, the Boston Heart MPO test does not require a separate sample tube, nor do office staff need to spend time aliquoting. Patients may benefit from having fewer tubes of blood drawn, and the risk of specimen rejection and redraw may be reduced, since aliquoting can be a cause of insufficient sample.
Boston Heart Diagnostics Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 03:00 PM
Jan 10 14
Boston Heart Diagnostics Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 03:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Susan Hertzberg, Chief Executive Officer, President and Director.
Boston Heart Diagnostics Corporation Launches New Genotype Test to Identify Those at Increased Risk for Developing Debilitating Myopathy as a Side Effect from Prescription Use of Statin Drugs
May 30 12
Boston Heart Diagnostics Corporation announced the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation. This adds to the company's IP portfolio and suite of cardiovascular disease (CVD)-focused tests that are designed to improve outcomes for patients and save health dollars by tailoring a therapeutic regimen to the patient's particular circumstances. The new test, which BHD offers through its Framingham-based CLIA lab, identifies patients who are at higher risk for developing severe myopathy (muscle aches and pain) as a side effect of statin drugs prescribed to reduce low-density lipoprotein cholesterol (LDL-C) levels. Oxford University made the SLCO1B1 discovery and has granted BHD an exclusive U.S. license for the marker. Additionally, the U.S. Patent and Trademark Office has approved the patent application for Prioritized Examination under its fast-track patent examination program. A final decision is expected before the end of 2012.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|